Medicenna Therapeutics (MDNA) Competitors

Medicenna Therapeutics (TSE:MDNA) and Aimia (TSE:AIM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, community ranking, dividends, valuation and earnings.

Which has more volatility & risk, MDNA or AIM?

Medicenna Therapeutics has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, Aimia has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Do analysts prefer MDNA or AIM?

Aimia has a consensus target price of C$4.00, suggesting a potential upside of 53.85%. Given Aimia's stronger consensus rating and higher probable upside, analysts plainly believe Aimia is more favorable than Medicenna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicenna Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aimia	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to MDNA or AIM?

In the previous week, Aimia had 4 more articles in the media than Medicenna Therapeutics. MarketBeat recorded 5 mentions for Aimia and 1 mentions for Medicenna Therapeutics. Medicenna Therapeutics' average media sentiment score of 0.75 beat Aimia's score of 0.66 indicating that Medicenna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medicenna Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aimia	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher valuation and earnings, MDNA or AIM?

Medicenna Therapeutics has higher earnings, but lower revenue than Aimia. Aimia is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicenna Therapeutics	C$4.87K	15,060.17	-C$25.98M	-C$0.36	-2.70
Aimia	C$464.71M	0.54	-C$78.81M	-C$0.81	-3.20

Do institutionals & insiders have more ownership in MDNA or AIM?

13.0% of Medicenna Therapeutics shares are owned by institutional investors. Comparatively, 31.6% of Aimia shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by insiders. Comparatively, 3.3% of Aimia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is MDNA or AIM more profitable?

Aimia has a net margin of -16.96% compared to Medicenna Therapeutics' net margin of -533,640.00%. Aimia's return on equity of -14.38% beat Medicenna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicenna Therapeutics	-533,640.00%	-159.88%	-32.80%
Aimia	-16.96%	-14.38%	-4.93%

Does the MarketBeat Community prefer MDNA or AIM?

Aimia received 301 more outperform votes than Medicenna Therapeutics when rated by MarketBeat users. However, 68.22% of users gave Medicenna Therapeutics an outperform vote while only 54.18% of users gave Aimia an outperform vote.

Company	Underperform	Outperform
Medicenna Therapeutics	Outperform Votes 88 68.22%	Underperform Votes 41 31.78%
Aimia	Outperform Votes 389 54.18%	Underperform Votes 329 45.82%

Summary

Aimia beats Medicenna Therapeutics on 10 of the 18 factors compared between the two stocks.